SKYE

Skye Bioscience, Inc. SKYE

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-10.79M

Quarter to Jun 30

Free cash flow

$-7.12M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$11.11M total
5AM Venture Management, LLC
$6.71M0.0%
Versant Venture Management, LLC
$1.39M0.0%
BAKER BROS. ADVISORS LP
$1.09M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$529.4K-0.1%
SPHERA FUNDS MANAGEMENT LTD.
$470.7K0.0%
PLATINUM INVESTMENT MANAGEMENT LTD
$161.6K0.0%
BlackRock, Inc.
$161.5K-18.6%
GEODE CAPITAL MANAGEMENT, LLC
$151.2K-21.4%
MILLENNIUM MANAGEMENT LLC
$137.6K-23.1%
VANGUARD FIDUCIARY TRUST CO
$72.2K0.0%
STATE STREET CORP
$51.2K-2.0%
UBS Group AG
$51.1K+61.3%
NORTHERN TRUST CORP
$39.1K+179.6%
Qube Research & Technologies Ltd
$29.9KNew
SIMPLEX TRADING, LLC
$18.7KNew
XTX Topco Ltd
$14.6K-48.7%
Engineers Gate Manager LP
$14.0K0.0%
GROUP ONE TRADING, L.P.
$3.2K-36.3%
Vanguard Global Advisers, LLC
$3.2K0.0%
MORGAN STANLEY
$1.7K-3.1%
BARCLAYS PLC
$455-96.4%
OSAIC HOLDINGS, INC.
$4130.0%
NATIONAL BANK OF CANADA /FI/
$2750.0%
JPMORGAN CHASE & CO
$440.0%
Zurcher Kantonalbank (Zurich Cantonalbank)
$360.0%
See all 43 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SKYE

Earnings Per Share

13fpro.ai/company/SKYE

Loading ratio trend…

SKYE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Skye Bioscience, Inc. (SKYE): stock profile, AI score and financials

Skye Bioscience, Inc. (SKYE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SKYE is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Skye Bioscience, Inc. reports net income of $-10.8M, free cash flow of $-7.1M. Top institutional holders of SKYE by reported 13-F value include 5AM Venture Management, Versant Venture Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. SKYE trades on the Nasdaq exchange and files with the SEC under CIK 1516551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SKYE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Skye Bioscience, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1516551 →